Dopamine D3 receptor ligands for drug addiction treatment: Update on recent findings

Progress in Brain Research

Volumn 211, Issue , 2014, Pages 255-275

  Le Foll, Bernard ^a,b   Collo, Ginetta ^c   Rabiner, Eugenii A ^d,e   Boileau, Isabelle ^a   Merlo Pich, Emilio ^f   Sokoloff, Pierre ^g  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF BRESCIA   (Italy)

^d Imanova Ltd   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Animal model; Dopamine; Human clinical trial; Motivation; Occupancy; PET imaging; Reinstatement

Indexed keywords

AMPHETAMINE; BRAIN DERIVED NEUROTROPHIC FACTOR; BUSPIRONE; COCAINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; GSK 598809; N [4 [2 (6 CYANO 1,2,3,4 TETRAHYDRO 2 ISOQUINOLINYL)ETHYL]CYCLOHEXYL] 4 QUINOLINECARBOXAMIDE; N [4 [2 (8 CYANO 1,3A,4,9B TETRAHYDRO 1 BENZOPYRANO[3,4 C]PYRROL 2(3H) YL)ETHYL]PHENYL]ACETAMIDE; NAXAGOLIDE; NICOTINE; RADIOLIGAND; DOPAMINE 3 RECEPTOR; LIGAND;

ARTICLE; CAUDATE NUCLEUS; CELL GROWTH; CELL SURVIVAL; COGNITION; CORPUS STRIATUM; DOPAMINE RECEPTOR BLOCKING; DOPAMINERGIC NERVE CELL; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG SEEKING BEHAVIOR; HUMAN; HYPOTHALAMUS; INTRACELLULAR SIGNALING; MESENCEPHALON; MOLECULAR IMAGING; MOTOR CONTROL; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; SMOKING; UPREGULATION; ADDICTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; BRAIN; HUMANS; LIGANDS; RECEPTORS, DOPAMINE D3; SUBSTANCE-RELATED DISORDERS;

EID: 84904631057     PISSN: 00796123     EISSN: 18757855     Source Type: Book Series    
DOI: 10.1016/B978-0-444-63425-2.00011-8     Document Type: Chapter

References (103)

1. Achat-Mendes C., Grundt P., Cao J., Platt D.M., Newman A.H., Spealman R.D. Dopamine D3 and D2 receptor mechanisms in the abuse-related behavioral effects of cocaine: studies with preferential antagonists in squirrel monkeys. J. Pharmacol. Exp. Ther. 2010, 334:556-565.
2. Andreoli M., Tessari M., Pilla M., Valerio E., Hagan J.J., Heidbreder C.A. Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior. Neuropsychopharmacology 2003, 28:1272-1280.
3. Apter J.T., Allen L.A. Buspirone: future directions. J. Clin. Psychopharmacol. 1999, 19(1):86-93. Review.
4. Bergman J., Roof R.A., Furman C.A., Conroy J.L., Mello N.K., Sibley D.R., Skolnick P. Modification of cocaine self-administration by buspirone (buspar(R)): potential involvement of D3 and D4 dopamine receptors. Int. J. Neuropsychopharmacol. 2013, 16:445-458.
5. Boileau I., Payer D., Houle S., Behzadi A., Rusjan P.M., Tong J., Wilkins D., Selby P., George T.P., Zack M., Furukawa Y., Mccluskey T., Wilson A.A., Kish S.J. Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J. Neurosci. 2012, 32:1353-1359.
6. Boileau I., Payer D., Chugani B., Lobo D., Behzadi A., Rusjan P.M., Houle S., Wilson A.A., Warsh J., Kish S.J., Zack M. The D2/3 dopamine receptor in pathological gambling: a positron emission tomography study with [11C]-(+)-propyl-hexahydro-naphtho-oxazin and [11C]raclopride. Addiction 2013, 108:953-963.
7. 2 receptor mRNA. Brain Res. 1991, 564:203-219.
8. Brennan K.A., Carati C., Lea R.A., Fitzmaurice P.S., Schenk S. Effect of D1-like and D2-like receptor antagonists on methamphetamine and 3,4-methylenedioxymethamphetamine self-administration in rats. Behav. Pharmacol. 2009, 20:688-694.
9. Bruno F. Buspirone in the treatment of alcoholic patients. Psychopathology 1989, 22(Suppl. 1):49-59.
10. Cervo L., Cocco A., Petrella C., Heidbreder C.A. Selective antagonism at dopamine D3 receptors attenuates cocaine-seeking behaviour in the rat. Int. J. Neuropsychopharmacol. 2007, 10:167-181.
11. Collo G., Zanetti S., Missale C., Spano P. Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation. Eur. J. Neurosci. 2008, 28:1231-1240.
12. Collo G., Bono F., Cavalleri L., Plebani L., Merlo Pich E., Millan M.J., Spano P.F., Missale C. Pre-synaptic dopamine D(3) receptor mediates cocaine-induced structural plasticity in mesencephalic dopaminergic neurons via ERK and Akt pathways. J. Neurochem. 2012, 120:765-778.
13. Collo G., Bono F., Cavalleri L., Plebani L., Mitola S., Merlo Pich E., Millan M.J., Zoli M., Maskos U., Spano P., Missale C. Nicotine-induced structural plasticity in mesencephalic dopaminergic neurons is mediated by dopamine D3 receptors and Akt-mTORC1 signaling. Mol. Pharmacol. 2013, 83:1176-1189.
14. Diaz J., Pilon C., Le Foll B., Gros C., Triller A., Schwartz J.C., Sokoloff P. Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J. Neurosci. 2000, 20:8677-8684.
15. Di Ciano P., Underwood R.J., Hagan J.J., Everitt B.J. Attenuation of cue-controlled cocaine-seeking by a selective D3 dopamine receptor antagonist SB-277011-A. Neuropsychopharmacology 2003, 28:329-338.
16. Dodds C.M., O'neill B., Beaver J., Makwana A., Bani M., Merlo-Pich E., Fletcher P.C., Koch A., Bullmore E.T., Nathan P.J. Effect of the dopamine D3 receptor antagonist GSK598809 on brain responses to rewarding food images in overweight and obese binge eaters. Appetite 2012, 59:27-33.
17. Foulon C., Kung M.P., Kung H.F. Synthesis of (R, S)-2'-trans-7-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-propenyl)-amino]tetralin (trans-7-OH-PIPAT): a new D3 dopamine receptor ligand. J. Med. Chem. 1993, 36:1499-1500.
18. Frankle W.G., Laruelle M. Neuroreceptor imaging in psychiatric disorders. Ann. Nucl. Med. 2002, 16:437-446.
19. 3 dopamine receptor. J. Pharmacol. Exp. Ther. 1994, 268:417-426.
20. Gal K., Gyertyan I. Targeting the dopamine D3 receptor cannot influence continuous reinforcement cocaine self-administration in rats. Brain Res. Bull. 2003, 61:595-601.
21. Gal K., Gyertyan I. Dopamine D3 as well as D2 receptor ligands attenuate the cue-induced cocaine-seeking in a relapse model in rats. Drug Alcohol Depend. 2006, 81:63-70.
22. Gallezot J.D., Beaver J.D., Gunn R.N., Nabulsi N., Weinzimmer D., Singhal T., Slifstein M., Fowles K., Ding Y.S., Huang Y., Laruelle M., Carson R.E., Rabiner E.A. Affinity and selectivity of [(1)(1)C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo. Synapse 2012, 66:489-500.
23. Giannini A.J., Loiselle R.H., Graham B.H., Folts D.J. Behavioral response to buspirone in cocaine and phencyclidine withdrawal. J. Subst. Abuse Treat. 1993, 10:523-527.
24. Gilbert J.G., Newman A.H., Gardner E.L., Ashby C.R., Heidbreder C.A., Pak A.C., Peng X.Q., Xi Z.X. Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors. Synapse 2005, 57:17-28.
25. Girgis R.R., Xu X., Miyake N., Easwaramoorthy B., Gunn R.N., Rabiner E.A., Abi-Dargham A., Slifstein M. In vivo binding of antipsychotics to D(3) and D(2) receptors: a PET study in baboons with [(11)C]-(+)-PHNO. Neuropsychopharmacology 2011, 36:887-895.
26. 3 receptor and chromosome identification. C. R. Acad. Sci. III 1990, 311:501-508.
27. Graff-Guerrero A., Redden L., Abi-Saab W., Katz D.A., Houle S., Barsoum P., Bhathena A., Palaparthy R., Saltarelli M.D., Kapur S. Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. Int. J. Neuropsychopharmacol. 2010, 13:273-287.
28. Gross G., Wicke K., Drescher K.U. Dopamine D(3) receptor antagonism-still a therapeutic option for the treatment of schizophrenia. Naunyn Schmiedebergs Arch. Pharmacol. 2013, 386:155-166.
29. Grundt P., Prevatt K.M., Cao J., Taylor M., Floresca C.Z., Choi J.K., Jenkins B.G., Luedtke R.R., Newman A.H. Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents. J. Med. Chem. 2007, 50:4135-4146.
30. Heidbreder C.A., Gardner E.L., Xi Z.X., Thanos P.K., Mugnaini M., Hagan J.J., Ashby C.R. The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Res. Brain Res. Rev. 2005, 49:77-105.
31. Heidbreder C.A., Andreoli M., Marcon C., Hutcheson D.M., Gardner E.L., Ashby C.R. Evidence for the role of dopamine D3 receptors in oral operant alcohol self-administration and reinstatement of alcohol-seeking behavior in mice. Addict. Biol. 2007, 12:35-50.
32. Higley A.E., Kiefer S.W., Li X., Gaal J., Xi Z.X., Gardner E.L. Dopamine D(3) receptor antagonist SB-277011A inhibits methamphetamine self-administration and methamphetamine-induced reinstatement of drug-seeking in rats. Eur. J. Pharmacol. 2011, 659:187-192.
33. Joyce J.N. Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol. Ther. 2001, 90:231-259.
34. Joyce J.N., Millan M.J. Dopamine D3 receptor agonists for protection and repair in Parkinson's disease. Curr. Opin. Pharmacol. 2007, 7:100-105.
35. Khaled M.A., Farid Araki K., Li B., Coen K.M., Marinelli P.W., Varga J., Gaal J., Le Foll B. The selective dopamine D3 receptor antagonist SB 277011-A, but not the partial agonist BP 897, blocks cue-induced reinstatement of nicotine-seeking. Int. J. Neuropsychopharmacol. 2010, 13:181-190.
36. Kranzler H.R., Burleson J.A., Del Boca F.K., Babor T.F., Korner P., Brown J., Bohn M.J. Buspirone treatment of anxious alcoholics. A placebo-controlled trial. Arch. Gen. Psychiatry 1994, 51:720-731.
37. Kula N.S., Baldessarini R.J., Kebabian J.W., Neumeyer J.L. S-(+)-aporphines are not selective for human D3 dopamine receptors. Cell. Mol. Neurobiol. 1994, 14:185-191.
38. Le Foll B., Boileau I. Repurposing buspirone for drug addiction treatment. Int. J. Neuropsychopharmacol. 2013, 16:251-253.
39. Le Foll B., Schwartz J.-C., Sokoloff P. Dopamine D3 receptor agents as potential new medications for drug addiction. Eur. Psychiatry 2000, 15:140-146.
40. Le Foll B., Francès H., Diaz J., Schwartz J.-C., Sokoloff P. Role of the dopamine D3 receptor in reactivity to cocaine-associated cues in mice. Eur. J. Neurosci. 2002, 15:2016-2026.
41. Le Foll B., Diaz J., Sokoloff P. Increased dopamine D3 receptor expression accompanying behavioural sensitization to nicotine in rats. Synapse 2003, 47:176-183.
42. Le Foll B., Schwartz J.-C., Sokoloff P. Disruption of nicotine conditioning by dopamine D3 receptor ligands. Mol. Psychiatry 2003, 8:225-230.
43. Le Foll B., Diaz J., Sokoloff P. Neuroadaptations to hyperdopaminergia in dopamine D3 receptor deficient mice. Life Sci. 2005, 76:1281-1296.
44. Le Foll B., Diaz J., Sokoloff P. A single cocaine exposure increases BDNF and D3 receptor expressions: implications for drug-conditioning. Neuroreport 2005, 16:175-178.
45. Le Foll B., Goldberg S.R., Sokoloff P. The dopamine D3 receptor and drug dependence: effects on reward or beyond?. Neuropharmacology 2005, 49:525-541.
46. Le Foll B., Sokoloff P., Stark H., Goldberg S.R. Dopamine D3 receptor ligands block nicotine-induced conditioned place preferences through a mechanism that does not involve discriminative-stimulus or antidepressant-like effects. Neuropsychopharmacology 2005, 30:720-730.
47. Le Foll B., Goldberg S.R., Sokoloff P. Dopamine D3 receptor ligands for the treatment of tobacco dependence. Expert Opin. Investig. Drugs 2007, 16:45-57.
48. Le Foll B., Gallo A., Le Strat Y., Lu L., Gorwood P. Genetics of dopamine receptors and drug addiction: a comprehensive review. Behav. Pharmacol. 2009, 20:1-17.
49. Le Foll B., Guranda M., Wilson A.A., Houle S., Rusjan P.M., Wing V.C., Zawertailo L., Busto U., Selby P., Brody A.L., George T.P., Boileau I. Elevation of dopamine induced by cigarette smoking: novel insights from a [C]-(+)-PHNO PET study in humans. Neuropsychopharmacology 2014, 39(2):415-424.
50. Levant B. The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol. Rev. 1997, 49:231-252.
51. Lévesque D., Diaz J., Pilon C., Martres M.-P., Giros B., Souil E., Schott D., Morgat J.-L., Schwartz J.-C., Sokoloff P. Identification, characterization and localization of the dopamine D3 receptor in rat brain using 7-[3H]-hydroxy-N,N di-n-propyl-2-aminotetralin. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:8155-8159.
52. Malec T.S., Malec E.A., Dongier M. Efficacy of buspirone in alcohol dependence: a review. Alcohol. Clin. Exp. Res. 1996, 20:853-858.
53. Mcrae-Clark A.L., Carter R.E., Killeen T.K., Carpenter M.J., Wahlquist A.E., Simpson S.A., Brady K.T. A placebo-controlled trial of buspirone for the treatment of marijuana dependence. Drug Alcohol Depend. 2009, 105:132-138.
54. Mello N.K., Fivel P.A., Kohut S.J., Bergman J. Effects of chronic buspirone treatment on cocaine self-administration. Neuropsychopharmacology 2013, 38:455-467.
55. Micheli F., Heidbreder C. Dopamine D3 receptor antagonists: a patent review (2007-2012). Expert Opin. Ther. Pat. 2013, 23:363-381.
56. Millan M.J., Mannoury La Cour C., Novi F., Maggio R., Audinot V., Newman-Tancredi A., Cussac D., Pasteau V., Boutin J.A., Dubuffet T., Lavielle G. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors. J. Pharmacol. Exp. Ther. 2008, 324:587-599.
57. Mogg K., Bradley B.P., O'neill B., Bani M., Merlo-Pich E., Koch A., Bullmore E.T., Nathan P.J. Effect of dopamine D(3) receptor antagonism on approach responses to food cues in overweight and obese individuals. Behav. Pharmacol. 2012, 23:603-608.
58. Mueller D., Chapman C.A., Stewart J. Amphetamine induces dendritic growth in ventral tegmental area dopaminergic neurons in vivo via basic fibroblast growth factor. Neuroscience 2006, 137:727-735.
59. Mugnaini M., Iavarone L., Cavallini P., Griffante C., Oliosi B., Savoia C., Beaver J., Rabiner E.A., Micheli F., Heidbreder C., Andorn A., Merlo Pich E., Bani M. Occupancy of brain dopamine D3 receptors and drug craving: a translational approach. Neuropsychopharmacology 2013, 38:302-312.
60. 2 receptors to mesostriatal regions of human forebrain. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:11271-11275.
61. Nakajima S., Gerretsen P., Takeuchi H., Caravaggio F., Chow T., Le Foll B., Mulsant B., Pollock B., Graff-Guerrero A. The potential role of dopamine D3 receptor neurotransmission in cognition. Eur. Neuropsychopharmacol. 2013, 23(8):799-813.
62. Narendran R., Slifstein M., Guillin O., Hwang Y., Hwang D.R., Scher E., Reeder S., Rabiner E., Laruelle M. Dopamine (D(2/3)) receptor agonist positron emission tomography radiotracer [(11)C]-(+)-PHNO is a D(3) receptor preferring agonist in vivo. Synapse 2006, 60:485-495.
63. Nathan P.J., O'neill B.V., Mogg K., Bradley B.P., Beaver J., Bani M., Merlo-Pich E., Fletcher P.C., Swirski B., Koch A., Dodds C.M., Bullmore E.T. The effects of the dopamine D(3) receptor antagonist GSK598809 on attentional bias to palatable food cues in overweight and obese subjects. Int. J. Neuropsychopharmacol. 2012, 15:149-161.
64. Newman A.H., Grundt P., Nader M.A. Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J. Med. Chem. 2005, 48:3663-3679.
65. Newman A.H., Blaylock B.L., Nader M.A., Bergman J., Sibley D.R., Skolnick P. Medication discovery for addiction: translating the dopamine D3 receptor hypothesis. Biochem. Pharmacol. 2012, 84:882-890.
66. Nobrega J.N., Seeman P. Dopamine D2 receptors mapped in rat brain with [3H](+)PHNO. Synapse 1994, 17:167-172.
67. Orio L., Wee S., Newman A.H., Pulvirenti L., Koob G.F. The dopamine D3 receptor partial agonist CJB090 and antagonist PG01037 decrease progressive ratio responding for methamphetamine in rats with extended-access. Addiction Biol. 2010, 15(3):312-323. Epub 2010 Apr 29. http://dx.doi.org/j.1369-1600.2010.00211.x.
68. Pak A.C., Ashby C.R., Heidbreder C.A., Pilla M., Gilbert J., Xi Z.X., Gardner E.L. The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions. Int. J. Neuropsychopharmacol. 2006, 9:585-602.
69. Parsey R.V., Mann J.J. Applications of positron emission tomography in psychiatry. Semin. Nucl. Med. 2003, 33:129-135.
70. Payer D.E., Behzadi A., Kish S.J., Houle S., Wilson A.A., Rusjan P.M., Tong J., Selby P., George T.P., Mccluskey T., Boileau I. Heightened D3 dopamine receptor levels in cocaine dependence and contributions to the addiction behavioral phenotype: a positron emission tomography study with [C]-(+)-PHNO. Neuropsychopharmacology 2014, 39(2):311-318.
71. Preti A. BP-897 Bioprojet. Curr. Opin. Investig. Drugs 2000, 1:110-115.
72. Rabiner E.A., Sliftein M., Gunn R.N., Plisson C., Gentile G., Xu X., Huiban M., Bennacef I., Gee A.D., Laruelle M. Contribution of D3 receptors to the in vivo binding of [11C]PHNO in the primate brain. Neuroimage 2008, 41:T39.
73. Rabiner E.A., Slifstein M., Nobrega J., Plisson C., Huiban M., Raymond R., Diwan M., Wilson A.A., Mccormick P., Gentile G., Gunn R.N., Laruelle M.A. In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: studies in non-human primates and transgenic mice. Synapse 2009, 63:782-793.
74. Reavill C., Taylor S.G., Wood M.D., Ashmeade T., Austin N.E., Avenell K.Y., Boyfield I., Branch C.L., Cilia J., Coldwell M.C., Hadley M.S., Hunter A.J., Jeffrey P., Jewitt F., Johnson C.N., Jones D.N., Medhurst A.D., Middlemiss D.N., Nash D.J., Riley G.J., Routledge C., Stemp G., Thewlis K.M., Trail B., Vong A.K., Hagan J.J. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. J. Pharmacol. Exp. Ther. 2000, 294:1154-1165.
75. Rice O.V., Patrick J., Schonhar C.D., Ning H., Ashby C.R. The effects of the preferential dopamine D(3) receptor antagonist S33138 on ethanol binge drinking in C57BL/6J mice. Synapse 2012, 66:975-978.
76. Robarge M.J., Husbands S.M., Kieltyka A., Brodbeck R., Thurkauf A., Newman A.H. Design and synthesis of [(2,3-dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as novel ligands selective for the dopamine D3 receptor subtype. J. Med. Chem. 2001, 44:3175-3186.
77. Rose J.S., Branchey M., Wallach L., Buydens-Branchey L. Effects of buspirone in withdrawal from opiates. Am. J. Addict. 2003, 12:253-259.
78. Russo S.J., Dietz D.M., Dumitriu D., Morrison J.H., Malenka R.C., Nestler E.J. The addicted synapse: mechanisms of synaptic and structural plasticity in nucleus accumbens. Trends Neurosci. 2010, 33:267-276.
79. Sarti F., Borgland S.L., Kharazia V.N., Bonci A. Acute cocaine exposure alters spine density and long-term potentiation in the ventral tegmental area. Eur. J. Neurosci. 2007, 26:749-756.
80. Searle G., Beaver J.D., Comley R.A., Bani M., Tziortzi A., Slifstein M., Mugnaini M., Griffante C., Wilson A.A., Merlo-Pich E., Houle S., Gunn R., Rabiner E.A., Laruelle M. Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist. Biol. Psychiatry 2010, 68:392-399.
81. Searle G.E., Beaver J.D., Tziortzi A., Comley R.A., Bani M., Ghibellini G., Merlo-Pich E., Rabiner E.A., Laruelle M., Gunn R.N. Mathematical modelling of [(1)(1)C]-(+)-PHNO human competition studies. Neuroimage 2013, 68:119-132.
82. Seeman P., Ulpian C., Larsen R.D., Anderson P.S. Dopamine receptors labelled by PHNO. Synapse 1993, 14:254-262.
83. Seeman P., Ko F., Willeit M., Mccormick P., Ginovart N. Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors. Synapse 2005, 58:122-128.
84. Shaham Y., Shalev U., Lu L., De Wit H., Stewart J. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology 2003, 168:3-20.
85. 3) as a target for neuroleptics. Nature 1990, 347:146-151.
86. Sokoloff P., Diaz J., Le Foll B., Guillin O., Leriche L., Bezard E., Gross C. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. Curr. Drug Targets CNS Neurol. Disord. 2006, 5:25-43.
87. Song R., Yang R.F., Wu N., Su R.B., Li J., Peng X.Q., Li X., Gaal J., Xi Z.X., Gardner E.L. YQA14: a novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor-knockout mice. Addict. Biol. 2012, 17:259-273.
88. Thanos P.K., Katana J.M., Ashby C.R., Michaelides M., Gardner E.L., Heidbreder C.A., Volkow N.D. The selective dopamine D3 receptor antagonist SB-277011-A attenuates ethanol consumption in ethanol preferring (P) and non-preferring (NP) rats. Pharmacol. Biochem. Behav. 2005, 81:190-197.
89. Tollefson G.D., Montague-Clouse J., Tollefson S.L. Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone). J. Clin. Psychopharmacol. 1992, 12:19-26.
90. Tziortzi A.C., Searle G.E., Tzimopoulou S., Salinas C., Beaver J.D., Jenkinson M., Laruelle M., Rabiner E.A., Gunn R.N. Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy. Neuroimage 2011, 54:264-277.
91. Van Vliet L.A., Rodenhuis N., Dijkstra D., Wikstrom H., Pugsley T.A., Serpa K.A., Meltzer L.T., Heffner T.G., Wise L.D., Lajiness M.E., Huff R.M., Svensson K., Sundell S., Lundmark M. Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR,10bR)-(+)-trans-3,4,4a,10b-tetrahydro-4-n-propyl-2H,5H [1]b enzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907). J. Med. Chem. 2000, 43:2871-2882.
92. Vengeliene V., Leonardi-Essmann F., Perreau-Lenz S., Gebicke-Haerter P., Drescher K., Gross G., Spanagel R. The dopamine D3 receptor plays an essential role in alcohol-seeking and relapse. FASEB J. 2006, 20:2223-2233.
93. Volkow N.D., Fowler J.S., Wang G.J. The addicted human brain: insights from imaging studies. J. Clin. Invest. 2003, 111:1444-1451.
94. Volkow N.D., Fowler J.S., Wang G.J., Baler R., Telang F. Imaging dopamine's role in drug abuse and addiction. Neuropharmacology 2009, 56(Suppl. 1):3-8.
95. Vorel S.R., Ashby C.R.J., Paul M., Liu X., Hayes R., Hagan J.J., Middlemiss D.N., Stemp G., Gardner E.L. Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J. Neurosci. 2002, 22:9595-9603.
96. Weber B., Schlicker E., Sokoloff P., Stark H. Identification of the dopamine autoreceptor in the guinea-pig retina as D(2) receptor using novel subtype-selective antagonists. Br. J. Pharmacol. 2001, 133:1243-1248.
97. Wilson A.A., Mccormick P., Kapur S., Willeit M., Garcia A., Hussey D., Houle S., Seeman P., Ginovart N. Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J. Med. Chem. 2005, 48:4153-4160.
98. Woolverton W.L. Effects of a D1 and a D2 dopamine antagonist on the self-administration of cocaine and piribedil by rhesus monkeys. Pharmacol. Biochem. Behav. 1986, 24:531-535.
99. Xi Z.X., Gilbert J., Campos A.C., Kline N., Ashby C.R., Hagan J.J., Heidbreder C.A., Gardner E.L. Blockade of mesolimbic dopamine D(3) receptors inhibits stress-induced reinstatement of cocaine-seeking in rats. Psychopharmacology (Berl) 2004, 176(1):57-65. Epub 2004 Apr 9.
100. Xi Z.X., Gilbert J.G., Pak A.C., Ashby C.R., Heidbreder C.A., Gardner E.L. Selective dopamine D3 receptor antagonism by SB-277011A attenuates cocaine reinforcement as assessed by progressive-ratio and variable-cost-variable-payoff fixed-ratio cocaine self-administration in rats. Eur. J. Neurosci. 2005, 21:3427-3438.
101. Xi Z.X., Newman A.H., Gilbert J.G., Pak A.C., Peng X.Q., Ashby C.R., Gitajn L., Gardner E.L. The novel dopamine D3 receptor antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats. Neuropsychopharmacology 2006, 31:1393-1405.
102. Yokel R.A., Wise R.A. Increased lever pressing for amphetamine after pimozide in rats: implications for a dopamine theory of reward. Science 1975, 187:547-549.
103. Yuan J., Chen X., Brodbeck R., Primus R., Braun J., Wasley J.W., Thurkauf A. NGB 2904 and NGB 2849: two highly selective dopamine D3 receptor antagonists. Bioorg. Med. Chem. Lett. 1998, 8:2715-2718.